Holding(s) in Company

Sareum Holdings PLC
08 October 2007

                Sareum Holdings plc ("Sareum" or the "Company")


                                                                 8 October  2007

                              Holdings in Company


The Company was informed on 5 October 2007 that on that day Mr Joseph Edward
Craven purchased 750,000 Sareum ordinary shares of 0.025p at a price of 1.09p
per share and now holds 14,000,000 Sareum ordinary shares representing 3.04 per
cent. of the Company's total voting rights.

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange